Kamada’s (KMDA) Buy Rating Reiterated at Benchmark

Benchmark restated their buy rating on shares of Kamada (NASDAQ:KMDA) in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a $15.00 target price on the biotechnology company’s stock.

Other research analysts have also recently issued research reports about the company. Sidoti upgraded Kamada to a “hold” rating in a research report on Thursday, May 8th. StockNews.com lowered shares of Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 25th. Finally, HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Kamada in a research report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.67.

Kamada Stock Up 1.2%

Shares of KMDA stock opened at $6.94 on Thursday. The company has a market capitalization of $398.91 million, a price-to-earnings ratio of 24.79, a P/E/G ratio of 0.97 and a beta of 0.94. Kamada has a 12-month low of $4.74 and a 12-month high of $9.16. The firm has a fifty day moving average of $6.60 and a 200-day moving average of $6.60.

Kamada (NASDAQ:KMDA) last released its earnings results on Wednesday, May 14th. The biotechnology company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. The business had revenue of $44.02 million during the quarter, compared to the consensus estimate of $154.06 million. Kamada had a net margin of 9.92% and a return on equity of 6.30%. On average, equities analysts expect that Kamada will post 0.23 EPS for the current year.

Kamada Announces Dividend

The firm also recently announced a — dividend, which was paid on Monday, April 7th. Stockholders of record on Monday, March 17th were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Monday, March 17th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KMDA. JPMorgan Chase & Co. purchased a new stake in shares of Kamada during the fourth quarter worth $67,000. Trexquant Investment LP purchased a new stake in Kamada during the 1st quarter worth about $82,000. NewEdge Advisors LLC lifted its holdings in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 8,260 shares in the last quarter. Geode Capital Management LLC boosted its stake in Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 1,549 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in Kamada during the 1st quarter valued at about $206,000. Institutional investors own 20.38% of the company’s stock.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.